Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ischemic Heart Disease

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 94 articles: HTML format

Single Articles

June 2025
1. DAKIK HA
   Aspiration Thrombectomy for Coronary Stent Thrombosis.
   N Engl J Med. 2025;392:e52.
   PubMed    
   
   
   May 2025
2. JOLLY SS, d'Entremont MA, Mian R
   Colchicine and Spironolactone in Acute Myocardial Infarction. Reply.
   N Engl J Med. 2025;392:2075.
   PubMed    
   
   
   
3. JOLLY SS, d'Entremont MA, Lee SF
   Colchicine and Spironolactone in Acute Myocardial Infarction. Reply.
   N Engl J Med. 2025;392:2074-2075.
   PubMed    
   
   
   
4. GOLINO M, Van Tassell B, Abbate A
   Colchicine and Spironolactone in Acute Myocardial Infarction.
   N Engl J Med. 2025;392:2073-2074.
   PubMed    
   
   
   
5. KIDA Y
   Colchicine and Spironolactone in Acute Myocardial Infarction.
   N Engl J Med. 2025;392:2073.
   PubMed    
   
   
   
6. GU HQ, Jiang Y, Li H
   Colchicine and Spironolactone in Acute Myocardial Infarction.
   N Engl J Med. 2025;392:2072-2073.
   PubMed    
   
   
   
7. VAN TWIST DJL, Appelboom Y
   Colchicine and Spironolactone in Acute Myocardial Infarction.
   N Engl J Med. 2025;392:2072.
   PubMed    
   
   
   
8. STRIESSNIG J
   Colchicine and Spironolactone in Acute Myocardial Infarction.
   N Engl J Med. 2025;392:2071-2072.
   PubMed    
   
   
   
9. ZANNAD F
   Seeking Multiorgan Benefits with Cardiovascular-Kidney-Metabolic Drug Therapy.
   N Engl J Med. 2025;392:2061-2062.
   PubMed    
   
   
   
10. QIU Z, Li F, Sang H, Yuan G, et al
    Intravenous Tenecteplase before Thrombectomy in Stroke.
    N Engl J Med. 2025 May 21. doi: 10.1056/NEJMoa2503867.
    PubMed     Abstract available
    
    
    
11. NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025 May 7. doi: 10.1056/NEJMoa2415820.
    PubMed     Abstract available
    
    
    
12. RADER DJ
    Targeting Lipoprotein(a) - the Next Frontier in Cardiovascular Disease.
    N Engl J Med. 2025;392:1740-1742.
    PubMed    
    
    
    March 2025
13. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
    PubMed     Abstract available
    
    
    
14. MCGUIRE DK, Marx N, Mulvagh SL, Deanfield JE, et al
    Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
    N Engl J Med. 2025 Mar 29. doi: 10.1056/NEJMoa2501006.
    PubMed     Abstract available
    
    
    
15. KOTANIDIS CP, Maron DJ, Jernberg T
    Beta-Blocker Therapy after Acute Myocardial Infarction - To Block or Not to Block?
    N Engl J Med. 2025;392:1234-1236.
    PubMed    
    
    
    February 2025
16. RIDKER PM, Buring JE
    Biomarkers and 30-Year Cardiovascular Outcomes in Women. Reply.
    N Engl J Med. 2025;392:828.
    PubMed    
    
    
    
17. PEI C, Zhang W, Huang J
    Biomarkers and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2025;392:828.
    PubMed    
    
    
    
18. GUI C, Huang Y
    Biomarkers and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2025;392:827-828.
    PubMed    
    
    
    
19. CHO MS, Nam GB, Park DW
    Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease. Reply.
    N Engl J Med. 2025;392:826-827.
    PubMed    
    
    
    
20. SHIMAZU Y
    Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2025;392:826.
    PubMed    
    
    
    
21. GREMMEL T
    Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2025;392:826.
    PubMed    
    
    
    
22. KAWAI T, Williams WW, Elias N, Fishman JA, et al
    Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease.
    N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2412747.
    PubMed     Abstract available
    
    
    January 2025
23. SILVAIN J, Vicaut E, Montalescot G
    Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2025;392:100-101.
    PubMed    
    
    
    
24. CHI KY, Nanna MG
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2025;392:99.
    PubMed    
    
    
    
25. GASOWSKI J, Perera I, Piotrowicz K
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2025;392:99.
    PubMed    
    
    
    
26. VAN VOLLENHOVEN RF
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2025;392:99.
    PubMed    
    
    
    December 2024
27. PURI R
    The Art and Science of Managing Stable Coronary Artery Disease in Patients Undergoing TAVI.
    N Engl J Med. 2024;391:2267-2268.
    PubMed    
    
    
    
28. SALEH Y, Rios S
    Spontaneous Coronary-Artery Dissection.
    N Engl J Med. 2024;391:e54.
    PubMed    
    
    
    November 2024
29. FIORELLA D, Monteith SJ, Hanel R, Atchie B, et al
    Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma.
    N Engl J Med. 2024 Nov 20. doi: 10.1056/NEJMoa2409845.
    PubMed     Abstract available
    
    
    
30. JOLLY SS, d'Entremont MA, Lee SF, Mian R, et al
    Colchicine in Acute Myocardial Infarction.
    N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMoa2405922.
    PubMed     Abstract available
    
    
    
31. JOLLY SS, d'Entremont MA, Pitt B, Lee SF, et al
    Routine Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMoa2405923.
    PubMed     Abstract available
    
    
    
32. RUBIN EJ, Leopold J, Morrissey S
    NEJM at AHA - Routine Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMe2414472.
    PubMed    
    
    
    
33. SAPP JL, Tang ASL, Parkash R, Stevenson WG, et al
    Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2409501.
    PubMed     Abstract available
    
    
    October 2024
34. HEATON K, Zern EK, Spahillari A, Barrett CD, et al
    Case 34-2024: A 69-Year-Old Man with Dyspnea after Old Myocardial Infarction.
    N Engl J Med. 2024;391:1633-1641.
    PubMed    
    
    
    
35. ALKAISSI H, Nazari MA, Hadrava Vanova K, Uher O, et al
    Rapid Cardiovascular Response to Belzutifan in HIF2A-Mediated Paraganglioma.
    N Engl J Med. 2024;391:1552-1555.
    PubMed    
    
    
    
36. JERNBERG T
    Routine Beta-Blockers in Secondary Prevention - Approaching Retirement?
    N Engl J Med. 2024;391:1356-1357.
    PubMed    
    
    
    September 2024
37. HABIB M, Aronson D
    Electrocardiographic Findings in Diffuse Subendocardial Ischemia.
    N Engl J Med. 2024;391:e19.
    PubMed    
    
    
    
38. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Invasive versus Conservative Strategy for Older Patients with Myocardial Infarction.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2410900.
    PubMed    
    
    
    
39. KUNADIAN V, Mossop H, Shields C, Bardgett M, et al
    Invasive Treatment Strategy for Older Patients with Myocardial Infarction.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407791.
    PubMed     Abstract available
    
    
    
40. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2410903.
    PubMed    
    
    
    
41. LIP GYH
    Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2409696.
    PubMed    
    
    
    
42. CHO MS, Kang DY, Ahn JM, Yun SC, et al
    Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407362.
    PubMed     Abstract available
    
    
    August 2024
43. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Inflammation, Cholesterol, Lipoprotein(a) and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMe2410895.
    PubMed    
    
    
    
44. BLUMENTHAL RS, Martin SS
    Prevention of Cardiovascular Disease - Don't Stop Thinking about Tomorrow.
    N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMe2409080.
    PubMed    
    
    
    
45. RIDKER PM, Moorthy MV, Cook NR, Rifai N, et al
    Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2405182.
    PubMed     Abstract available
    
    
    
46. LONBORG J, Jabbari R, Sabbah M, Veien KT, et al
    PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation.
    N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2401513.
    PubMed     Abstract available
    
    
    
47. SILVAIN J, Cayla G, Ferrari E, Range G, et al
    Beta-Blocker Interruption or Continuation after Myocardial Infarction.
    N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMoa2404204.
    PubMed     Abstract available
    
    
    
48. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Beta Blocker Interruption or Continuation with Prior Myocardial Infarction.
    N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMe2410891.
    PubMed    
    
    
    
49. MAHENDIRAN T, Collet C, De Bruyne B
    More on Coronary-Artery Autoregulation with Increasing Stenosis. Reply.
    N Engl J Med. 2024;391:671.
    PubMed    
    
    
    
50. YANG X, Wu M, Zhang G
    More on Coronary-Artery Autoregulation with Increasing Stenosis.
    N Engl J Med. 2024;391:670-671.
    PubMed    
    
    
    July 2024
51. BOHM F, James S
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction. Reply.
    N Engl J Med. 2024;391:288.
    PubMed    
    
    
    
52. LI P
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
    N Engl J Med. 2024;391:287-288.
    PubMed    
    
    
    
53. YNDIGEGN T, Hofmann R, Jernberg T
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. Reply.
    N Engl J Med. 2024;391:95.
    PubMed    
    
    
    
54. KOMAMURA K, Kobayashi K, Iwase M
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024;391:94-95.
    PubMed    
    
    
    
55. CLELAND JGF, McMurray JJV, Freemantle N
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024;391:94.
    PubMed    
    
    
    June 2024
56. MOLLER JE, Hassager C
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock. Reply.
    N Engl J Med. 2024;390:2328-2330.
    PubMed    
    
    
    
57. VON LEWINSKI D, Herold L, Toth GG
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2328.
    PubMed    
    
    
    
58. BALDETTI L, Pieri M, Scandroglio AM
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2328.
    PubMed    
    
    
    
59. ELKARYONI A, Hyder O, Saad M
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2327.
    PubMed    
    
    
    
60. FROM AM
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2327.
    PubMed    
    
    
    
61. MALLIDI J, Lotfi A
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2326-2327.
    PubMed    
    
    
    
62. THIELE H, Desch S, Zeymer U
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2325-2326.
    PubMed    
    
    
    
63. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:2227.
    PubMed    
    
    
    
64. MAAHS DM, Svensson J
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226-2227.
    PubMed    
    
    
    
65. WENSTEDT EFE, Vogt L
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226.
    PubMed    
    
    
    
66. LI S, Gu HQ, Li H, Wang X, et al
    Reteplase versus Alteplase for Acute Ischemic Stroke.
    N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2400314.
    PubMed     Abstract available
    
    
    
67. XIONG Y, Campbell BCV, Schwamm LH, Meng X, et al
    Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.
    N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2402980.
    PubMed     Abstract available
    
    
    
68. MAHENDIRAN T, Collet C, De Bruyne B
    Coronary-Artery Autoregulation with Increasing Stenosis.
    N Engl J Med. 2024;390:2030-2032.
    PubMed    
    
    
    May 2024
69. KING G, Hamilton GW
    Left Ventricular Thrombus after Anterior Myocardial Infarction.
    N Engl J Med. 2024;390:e50.
    PubMed    
    
    
    
70. NATARAJAN P
    Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease.
    N Engl J Med. 2024 May 29. doi: 10.1056/NEJMe2405647.
    PubMed    
    
    
    
71. ALBERS GW, Purdon B, Campbell BCV
    Tenecteplase for Stroke at 4.5 to 24 Hours. Reply.
    N Engl J Med. 2024;390:1729.
    PubMed    
    
    
    
72. GOYAL M, Bosshart SL, Ospel JM
    Tenecteplase for Stroke at 4.5 to 24 Hours.
    N Engl J Med. 2024;390:1729.
    PubMed    
    
    
    
73. GRINSPOON SK, Ribaudo HJ, Douglas PS
    Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection.
    N Engl J Med. 2024;390:1626-1628.
    PubMed    
    
    
    April 2024
74. STEG PG
    Routine Beta-Blockers in Secondary Prevention - On Injured Reserve.
    N Engl J Med. 2024;390:1434-1436.
    PubMed    
    
    
    
75. RAO SV
    Mechanical Circulatory Support in Cardiogenic Shock - Persistence and Progress.
    N Engl J Med. 2024;390:1436-1438.
    PubMed    
    
    
    
76. MOLLER JE, Engstrom T, Jensen LO, Eiskjaer H, et al
    Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:1382-1393.
    PubMed     Abstract available
    
    
    
77. BOHM F, Mogensen B, Engstrom T, Stankovic G, et al
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
    N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMoa2314149.
    PubMed     Abstract available
    
    
    
78. KUNADIAN V
    Role of Physiology in the Management of Nonculprit Lesions in Acute Coronary Syndrome.
    N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMe2403527.
    PubMed    
    
    
    
79. YNDIGEGN T, Lindahl B, Mars K, Alfredsson J, et al
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2401479.
    PubMed     Abstract available
    
    
    
80. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2402309.
    PubMed     Abstract available
    
    
    
81. GIBSON CM, Duffy D, Korjian S, Bahit MC, et al
    Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2400969.
    PubMed     Abstract available
    
    
    
82. ROULEAU J
    Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMe2402719.
    PubMed    
    
    
    
83. BUTLER J, Jones WS, Udell JA, Anker SD, et al
    Empagliflozin after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2314051.
    PubMed     Abstract available
    
    
    
84. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    PubMed    
    
    
    March 2024
85. WHITE HD
    A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
    N Engl J Med. 2024;390:10.
    PubMed    
    
    
    
86. AL-LAMEE RK, Rajkumar CA
    A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
    N Engl J Med. 2024;390:1151-1152.
    PubMed    
    
    
    
87. DURANTE A, Baiardo Redaelli M
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1150-1151.
    PubMed    
    
    
    
88. SHERROD CF 4TH, O'Keefe EL, Ikemura N
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1150.
    PubMed    
    
    
    
89. BESTERMANN WH JR
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1149-1150.
    PubMed    
    
    
    
90. ROSWELL RO, Wong MP, Stefanescu Schmidt AC, Petranovic M, et al
    Case 8-2024: A 55-Year-Old Man with Cardiac Arrest, Cardiogenic Shock, and Hypoxemia.
    N Engl J Med. 2024;390:1030-1043.
    PubMed    
    
    
    
91. CARSON JL, Brooks MM, Hebert PC
    Transfusion Strategy in Myocardial Infarction and Anemia. Reply.
    N Engl J Med. 2024;390:961-962.
    PubMed    
    
    
    
92. KHAN MS, Spertus JA, Chan PS
    Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2024;390:960-961.
    PubMed    
    
    
    
93. CHAPALAIN X, Aubron C
    Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2024;390:960.
    PubMed    
    
    
    
94. MARFELLA R, Prattichizzo F, Sardu C, Fulgenzi G, et al
    Microplastics and Nanoplastics in Atheromas and Cardiovascular Events.
    N Engl J Med. 2024;390:900-910.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge.